-

Weave Bio Launches AI-Powered Program Planner to Transform How Drug Developers Plan, Manage, and Adapt Development Strategies

The industry-leading capability extends Weave's platform to the earliest stages of drug development, helping teams identify critical planning gaps, anticipate regulatory challenges and adapt strategies as programs evolve

SAN FRANCISCO--(BUSINESS WIRE)--Weave Bio, the AI knowledge layer for regulatory data in drug development, today announced the launch of Program Planner, a new capability that helps therapeutics companies seamlessly leverage institutional knowledge, regulatory guidance and portfolio data to develop more informed and dynamic drug development strategies. The launch extends Weave's platform into the initial stages of drug development, beginning with candidate identification, enabling teams to apply foundational knowledge when early program decisions are being made.

“Program Planner delivers the change innovative companies deserve by functionalizing hard-won knowledge and making every new program smarter than the one before it."

Share

Drug development is one of the most complex and data-intensive processes in healthcare, requiring the coordination of years of research, regulatory guidance, and decisions across many functions including nonclinical, clinical, manufacturing, and regulatory teams. Over the course of a decade or more, this complexity compounds, creating inefficiency, slowness, and risks to program integrity. The knowledge needed to navigate these challenges is fragmented across documents, emails, systems, and individuals, making it difficult to access and apply when critical decisions are being made.

“Too many make-or-break decisions in drug development are made and remade again and again without the full benefit of the vast learnings bought and paid for by a company,” said Brandon Rice, co-founder and CEO of Weave Bio. “We believe Program Planner delivers the change innovative companies deserve by functionalizing hard-won knowledge and making every new program smarter than the one before it. By enabling our customers to make better, faster, more cost-effective decisions, we’re fulfilling our mission at Weave Bio to help new therapies reach patients who need them faster and more predictably than ever before.”

Program Planner brings together existing program materials, including storyboards, development plans, presentations, meeting notes and other documents, into a structured, interactive plan. Weave's AI analyzes the plan against relevant regulatory guidance and connected internal knowledge sources, identifying potential gaps, conflicting information, and areas of potential risk.

Teams can review recommendations linked to their program data, evaluate alternative approaches, and refine their development strategies as new information becomes available. This common source of truth also maintains a record of decisions and their supporting context, preserving program history and providing continuity throughout a program's development.

Program Planner is now available to select Weave customers.

To date, the company has supported more than 50 drug development programs and the completion of 12 FDA submissions, while helping customers achieve 60% overall timeline compression. To learn more, visit weave.bio.

About Weave

Weave Bio is an AI-native software company transforming how novel therapies navigate the complex path from lab to market. Drug development teams from sponsor to CRO leverage Weave as a knowledge layer for their program strategy, regulatory progression, and health authority communication. Founded in 2022 and headquartered in San Francisco, Weave is backed by leading investors including USVP, Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital, and trusted by innovative biopharma companies worldwide. For more information, visit weave.bio and follow us on LinkedIn.

Contacts

Molly Tobin, molly@weave.bio

Weave Bio


Release Versions

Contacts

Molly Tobin, molly@weave.bio

Social Media Profiles
More News From Weave Bio

Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities

SAN FRANCISCO--(BUSINESS WIRE)--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows. “Regulatory communications are the most knowledge-intensive workflows in all of drug development, and for too long that kn...

Weave Bio Expands Strategic Advisory Board with Two Former FDA Leaders

SAN FRANCISCO--(BUSINESS WIRE)--Weave Bio, a leader in AI-native regulatory automation for drug development, today announced the expansion of its Strategic Advisory Board (SAB) with the appointment of two former U.S. Food and Drug Administration leaders, Tala Fakhouri, Ph.D., M.P.H. chief AI and regulatory strategy officer at Parexel, and Sean Khozin, M.D., M.P.H., chief executive officer of the CEO Roundtable on Cancer and Project Data Sphere. Their appointments give the company firsthand insi...

Weave Bio Enables Global Submissions From a Single Source of Truth

SAN FRANCISCO--(BUSINESS WIRE)--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced new global submission capabilities that give drug development teams one connected platform for every regulatory filing across a program’s lifecycle, from an Investigational New Drug (IND) application and Clinical Trial Application (CTA) to a New Drug Application (NDA) and beyond. Available immediately, the enhancements establish a single source of truth across jurisdict...
Back to Newsroom